<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32867586</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-2032</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurodegenerative disease management</Title><ISOAbbreviation>Neurodegener Dis Manag</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>407</EndPage><MedlinePgn>397-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/nmt-2020-0026</ELocationID><Abstract><AbstractText><b>Background:</b> Mexiletine is a potential drug in amyotrophic lateral sclerosis (ALS)&#xa0;that has been tested in clinical trials. The objective of this study was to determine the efficacy and safety of mexiletine in ALS via systematic review of existing evidences. <b>Materials &amp; methods:</b> Relevant records were searched using major healthcare electronic databases. Data on functional disability, impairment, survival, muscle cramp frequency and severity, and adverse events were obtained. <b>Results &amp; conclusion:</b> Three relevant randomized controlled trials with 141 patients were included in this review. Mexiletine has no effect on the functional disability, impairment and survival in ALS. However, significant improvement in reducing muscle cramp severity and frequency was shown. The most common adverse effect associated with mexiletine intake&#xa0;among ALS patients&#xa0;are nausea (n&#xa0;=&#xa0;11, 7.8%) and tremors (n&#xa0;=&#xa0;5, 3.6%).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adiao</LastName><ForeName>Karen Joy</ForeName><Initials>KJB</Initials><Identifier Source="ORCID">0000-0001-5777-5171</Identifier><AffiliationInfo><Affiliation>Division of Adult Neurology, Department of Neurosciences, College of Medicine &amp; Philippine General Hospital, University of the Philippines Manila, Manila 1300, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espiritu</LastName><ForeName>Adrian</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0001-5621-1833</Identifier><AffiliationInfo><Affiliation>Division of Adult Neurology, Department of Neurosciences, College of Medicine &amp; Philippine General Hospital, University of the Philippines Manila, Manila 1300, Philippines.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila&#xa0;1300, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagnas</LastName><ForeName>Marjorie Anne</ForeName><Initials>MAC</Initials><Identifier Source="ORCID">0000-0003-2822-3196</Identifier><AffiliationInfo><Affiliation>Electromyography-Nerve Conduction Velocity (EMG-NCV) Unit, Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, University of the Philippines Manila, Manila&#xa0;1300, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurodegener Dis Manag</MedlineTA><NlmUniqueID>101517977</NlmUniqueID><ISSNLinking>1758-2024</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061567">Voltage-Gated Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="N">Mexiletine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009120" MajorTopicYN="N">Muscle Cramp</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061567" MajorTopicYN="N">Voltage-Gated Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">mexiletine</Keyword><Keyword MajorTopicYN="N">muscle cramps</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32867586</ArticleId><ArticleId IdType="doi">10.2217/nmt-2020-0026</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>